



**Telix Pharmaceuticals Limited**  
ACN 616 620 369  
Suite 401, 55 Flemington Road  
North Melbourne  
Victoria, 3051  
Australia

30 December 2022

**Notice under section 708A(5)(e) of the Corporations Act 2001  
Telix Pharmaceuticals Limited (ASX Code: TLX) (“Company”)**

Reference is made to the Appendix 2A released on 30 December 2022 and the issue of fully paid ordinary shares in Telix Pharmaceuticals Limited (“Shares”). For the purposes of section 708A(5)(e) of the Corporations Act, the Company gives notice that:

- (a) The Company issued Shares upon the exercise of unlisted Share Options as follows:

<b>Date of issue</b>	<b>Shares issued</b>	<b>Options exercised</b>
21/12/2022	43,236	59,433
<b>Total</b>	<b>43,236</b>	

- (b) The Company issued the shares without disclosure under part 6D.2 of the Corporations Act;
- (c) As at the date of this notice the Company has complied with the provisions of Chapter 2M of the Corporations Act as they apply to the Company and sections 674 and 674A of the Corporations Act; and
- (d) As at the date of this notice there is no information which is “excluded information” (as defined in sections 708A(7) and 708A(8) of the Corporations Act) which is required to be disclosed by the Company.

Authorised for release by

A handwritten signature in black ink, appearing to read "Genevieve Ryan".

Genevieve Ryan  
Company Secretary